|
Title
|
|
|
|
TCF7L2 polymorphism associates with new-onset diabetes after transplantation
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| New-onset diabetes after transplantation (NODAT) is a serious and frequent complication in transplant recipients. Whether NODAT shares the same susceptibility genes as type 2 diabetes is unknown. In this multicenter study, we genotyped 1076 white patients without diabetes at transplantation for 11 polymorphisms that associate with type 2 diabetes. We defined NODAT as a fasting plasma glucose >= 126 mg/dl on at least two occasions or de novo hypoglycemic therapy. We compared clinical and genetic factors between patients who developed NODAT within 6 mo of transplantation (n = 118; incidence 11 %) and patients without diabetes (n = 958). In multivariate analysis, NODAT significantly associated with the following characteristics: TCF7L2 polymorphism (odds ratio [OR] 1.60 per each T allele; P = 0.002), age (OR 1.03 per year; P < 0.001), body mass index at transplantation (OR 1.09 per unit; P < 0.001), tacrolimus use (OR 2.26; P < 0.001), and the occurrence of a corticoid-treated acute rejection episode (OR 2.78; P < 0.001). In summary, our data show that the TCF7L2 rs7903146 polymorphism, a known risk factor for type 2 diabetes in the general population, also associates with NODAT. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Journal of the American Society of Nephrology. - Baltimore, Md, 1990, currens
| |
|
Publication
|
|
|
|
Baltimore, Md
:
2009
| |
|
ISSN
|
|
|
|
1046-6673
| |
|
DOI
|
|
|
|
10.1681/ASN.2008121314
| |
|
Volume/pages
|
|
|
|
20
:11
(2009)
, p. 2459-2467
| |
|
ISI
|
|
|
|
000272261600023
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (publisher's version - intranet only)
|
|
|
|
| |
|